Biohaven Ltd.: insider trades · United States · SEC (Form 4)

About Biohaven Ltd.

Biohaven Ltd. (NYSE: BHVN) is a U.S.-listed biopharmaceutical company headquartered in New Haven, Connecticut, in the United States. The company’s current identity was shaped by a spin-off completed in 2022, following a long development history that includes licensing activity originating from Yale University and the build-out of proprietary drug-discovery platforms. Biohaven trades on the New York Stock Exchange under the BHVN ticker, making it a U.S. public-market name with a strong clinical-stage biotech profile. ([ir.biohaven.com](https://ir.biohaven.com/static-files/e1fdf95d-7215-455d-aaac-214c061b45fd)) Biohaven describes itself as a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments across three core therapeutic areas: neuroscience, immunology and oncology. Its business model is centered on a pipeline of innovative assets rather than a large established commercial franchise, which means valuation is driven primarily by clinical progress, regulatory milestones and eventual commercialization outcomes. The company emphasizes proprietary science and drug-development platforms, aiming to address both rare diseases and larger indications with substantial unmet medical need. ([biohaven.com](https://www.biohaven.com/)) Among the company’s most important assets are Nurtec ODT (rimegepant) and Zavzpret (zavegepant), which helped establish Biohaven’s credibility in migraine and broader neuro-related drug development. Biohaven’s pipeline also includes troriluzole, a lead program in spinocerebellar ataxia (SCA), where the company has been pursuing regulatory approval, and BHV-8000, a brain-penetrant, orally administered TYK2/JAK1 inhibitor currently in a Phase 2/3 study in early Parkinson’s disease. In immunology, BHV-1300 has generated data showing sustained IgG lowering and is being positioned as a potential first-in-class degrader platform. These programs give the company several shots on goal, but they also keep Biohaven exposed to the binary nature of biotech execution risk. ([ir.biohaven.com](https://ir.biohaven.com/node/11101/pdf)) From a competitive standpoint, Biohaven is best viewed as a science-driven specialty biotech rather than a diversified pharmaceutical major. Its differentiation lies in its ability to advance novel mechanisms and move candidates through late-stage development with a focus on neurologic and immunologic diseases. Geographically, the company remains centered in the United States, with its headquarters in New Haven and additional operating footprints that support research and development activities, including sites in the U.S. and Ireland. ([ir.biohaven.com](https://ir.biohaven.com/static-files/625aec92-2813-4aeb-bb2d-9bfc3fc5317a?utm_source=openai)) Recent headlines have been important for the investment case. In February 2025, the FDA accepted Biohaven’s NDA for troriluzole and granted Priority Review, a meaningful regulatory step for a rare-disease program. In May 2025, Biohaven initiated a global Phase 2/3 study of BHV-8000 in early Parkinson’s disease. The company also announced a non-dilutive financing agreement with Oberland Capital for up to $600 million, strengthening its balance sheet and potentially funding later-stage development and strategic flexibility. For investors, Biohaven remains a high-risk, catalyst-driven U.S. biotech story listed on the NYSE, with upside tied to clinical and regulatory execution. ([ir.biohaven.com](https://ir.biohaven.com/node/11101/pdf))